FDA accepts new drug application for ralinepag in PAH

The FDA accepted United Therapeutics’ new drug application for ralinepag, a once-daily oral prostacyclin, for the treatment of pulmonary arterial hypertension, according to a press release.The new drug application (NDA) included data from the multicenter, global, randomized, double-blind, placebo-controlled, event-driven phase 3 ADVANCE OUTCOMES trial, which were presented at the American

Raccontata damorningstar.comhealio.com